Tumor Genomic Profiling with Agilent SureSelect Cancer Assays
agilent technologies SPONSORED CONTENT

Tumor Genomic Profiling with Agilent SureSelect Cancer Assays

BlueskyReddit

Unlock the full potential of comprehensive genomic profiling (CGP) to advance precision oncology with the Agilent SureSelect Cancer assays, a portfolio of targeted resequencing assays based on next-generation sequencing (NGS) technology. The SureSelect Cancer portfolio includes catalog and custom panels for mutation detection in cancer-associated genes from solid tumors. You'll have access to the most clinically relevant and up-to-date biomarkers with gene content curated globally in consultation with leading cancer researchers, and drawing from established clinical guidelines, ongoing clinical trials, and somatic cancer databases.

The SureSelect Cancer assays enable you to detect key classes of somatic variants and assess immuno-oncology biomarkers and homologous recombination deficiency. Have confidence in high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimum sample input. The workflow solution is configurable to meet the needs of your lab with options to incorporate sample and NGS library QC, automation, and data analysis solutions. Download now to learn more.

Download Now

    Please fill out the information below to request information on the content you selected. If you are already registered, or have requested a quote before, and this information will be filled out for you..
  • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.